Table 1.
Autologous hematopoietic stem cell transplantation indications and engraftment syndrome
| Author/year of study | Country | Indications of Auto-SCT | Transplant Type | Total population | Es/no ES |
|---|---|---|---|---|---|
| Katzel et al. (2006) [30] | USA | MM | Autologous (Auto-SCT) | 90 (100%) | 9(10%)/80(90%) |
| Cornell et al. (2013) [21] | USA | MM/HL/NHL | Autologous (Auto-SCT) | 591 (100%) | 131(22%)/460(78%) |
| Gonzalo et al. (2018) [31] | Spain | MM | Autologous (Auto-SCT) | 170 (100%) | 73 (43%)/97(57%) |
| Irazabal et al. (2011) [32] | USA | Amyloidosis | Autologous (Auto-SCT) | 377 (100%) | 29 (8%)/348(92%) |
| Crreras et al. (2010) [33] | Spain | Amyloidosis, MM, HL, NHL, POEMS, CLL, acute leukemia | Autologous (Auto-SCT) | 328 (100%) | 42*(12.8%)/328 (87.2%) |
| Dispenzieri et al. (2008) [34] | USA | POEM syndrome | Autologous (Auto-SCT) | 30 (100%) | 15 (50%)/15 (50%) |
MM: Multiple Myeloma, HL: Hodgkin Lymphoma, NHL: Non-Hodgkin Lymphoma, CLL: Chronic Lymphoblastic Leukaemia, POEMS: Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein, Skin changes, ASCT: Autologous Stem Cell Transplantation, ES: Engraftment syndrome. (*) represent the exclusion of 1 patient who did not develop fever due to prior 48 h administration of steroids so, a total of 42 patients were included out of 43 (42/43)